Open AccessRecombinant Human Erythropoietin: Manfaat dalam Bidang Kedokteran
Author(s) -
Yanuartono Yanuartono,
Hary Purnamaningsih,
Alfarisa Nururrozi,
Soedarmanto Indarjulianto,
Slamet Raharjo
Publication year - 2019
Publication title -
jurnal sain veteriner
Language(s) - English
Resource type - Journals
eISSN - 2443-1583
pISSN - 2407-3733
DOI - 10.22146/jsv.48516
Subject(s) - medicine , erythropoietin , anemia , human medicine , chronic renal failure , cats , recombinant dna , intensive care medicine , transfusion medicine , traditional medicine , blood transfusion , biochemistry , chemistry , gene
Recombinant human erythropoietin (rhEPO) is one of the biotechnology-based drugs that are needed by the human medicine and has also been used in the veterinary medicine. Currently RhEPO has been widely used in the world of human medicine for the treatment of anaemia caused by renal failure, cancer, chronic inflammation and AIDS. In veterinary medicine, although there is still not much data on its achievements, rhEPO has also been used for cases of chronic renal failure in dogs and cats. However, since rhEPO is not identical to feline EPO and canine EPO, some patients eventually produce antibodies against the drug. The antibodies not only prevent EPO therapy from being effective, but also may lead to severe and life-threatening anemia. This paper provides a review of the use of RhEPO, rfEPO and rcEPO in veterinary medicine, especially for the purpose of non-regenerative anemia therapy in cases of chronic renal failure in dogs and cats.